This content is from: Trademarks

Pharma counsel still wary of non-traditional TMs despite benefits

Counsel at pharmaceutical companies say non-traditional marks can play an important role in portfolio management, but that regulatory concerns remain

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial